Vanguard Global Advisers
GYRE icon

Vanguard Global Advisers’s Gyre Therapeutics GYRE Stock Holding History

Vanguard Global Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.8K Hold
9,983
– – ﹤0.01% 2966
2026
Q1 		$69.6K Buy
+9,983
New +$77.5K ﹤0.01% 2875

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's GYRE Position: Q2 2026 in Review

Vanguard Global Advisers held its Gyre Therapeutics (GYRE) position steady in Q2 2026 at 9,983 shares worth $65.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.

Vanguard Global Advisers first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $69.6K in Q1 2026. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Vanguard Global Advisers held 9,983 shares of Gyre Therapeutics worth $65.8K as of Q2 2026.
  • Vanguard Global Advisers left its Gyre Therapeutics share count unchanged in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2966 holding.
  • Vanguard Global Advisers first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Gyre Therapeutics position peaked at $69.6K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.